# Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines

> **NCT01189747** · PHASE3 · COMPLETED · sponsor: **Allergan** · enrollment: 446 (actual)

## Conditions studied

- Lateral Canthus Rhytides
- Crow's Feet Lines

## Interventions

- **BIOLOGICAL:** onabotulinumtoxinA
- **DRUG:** normal saline

## Key facts

- **NCT ID:** NCT01189747
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10-01
- **Primary completion:** 2011-04-01
- **Final completion:** 2011-07-01
- **Target enrollment:** 446 (ACTUAL)
- **Last updated:** 2019-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01189747

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01189747, "Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01189747. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*